The vaccine proves safe in a small sample of human subjects, opening the way for the next phase of testing
A new colorectal cancer vaccine showed positive results in the phase 1 clinical trial to demonstrate that the approach is safe. The patients treated had no signs of serious adverse events and samples of their blood contained markers of immune activation — an early indication that the vaccine could activate immune cells to fight colorectal tumors and metastases. Further tests to determine if the vaccine is effective at slowing tumor growth are forthcoming.
The results were published in the Journal for ImmunoTherapy of Cancer.
Colon cancer, especially in younger people, is on the rise and is currently the second highest cause of cancer deaths in the US and worldwide. Surgery can cure the disease in many patients, but prognosis is poor for those with recurrence of their disease. If it proves effective in larger-scale trials the vaccine, developed by researchers at Jefferson (Philadelphia University + Thomas Jefferson University), could train the patient’s immune system to attack the colon cancer that had already spread before the surgery.
“There is an urgent need to understand what fuels colorectal cancer growth, and to harness that knowledge for developing novel therapies. This pivotal study provides some of the first evidence that it may be possible to safely direct a patient’s own immune system to seek and destroy this cancer type. This is a true milestone– made possible through the scientists and clinicians in our colorectal cancer team working in synchrony”, said Karen E. Knudsen, PhD, EVP of Oncology Services and Director of the Sidney Kimmel Cancer Center — Jefferson Health.
In earlier preclinical work in mice, Jefferson researchers demonstrated how the design of their vaccine worked. Tumor vaccines have historically been developed against a sort of molecular sign-post for cancer. Because they come from normal cells, cancer cells share nearly all of the same molecules, making it difficult for the immune system to differentiate normal from cancerous. Tumor antigens are molecules that the immune system can recognize as different from normal. In colorectal cancer, one such molecule called GUCY2C, was identified by Scott Waldman, MD, PhD, the Samuel M.V. Hamilton Professor and Director of the Gastrointestinal Cancer Program of the Sidney Kimmel Cancer Center — Jefferson Health.
The vaccine developed by first author, Adam Snook, PhD, Assistant Professor in the Department of Pharmacology and Experimental Therapeutics, Dr. Waldman and others, works by activating the immune system against the GUCY2C molecule. By joining the GUCY2C molecule with a molecule that boosts the immune reaction called PADRE, and loading it into an adenovirus vector, the researchers engineered a vaccine that could specifically target the colon cancer.
The current clinical trial enrolled 10 patients with stage I or II colon cancer. Patients were given one dose and came back for blood draws 30, 90, 180 days after immunization. Patients experienced some discomfort at the injection site, but reported no serious side effects of the vaccine. The blood samples showed activation of “killer T cells,” the immune cell type the researchers had expected. These killer T cells are responsible for finding and killing colon cancer cells that are responsible for causing the cancer to come back.
“We are preparing for a phase II study that will begin recruiting patients this fall,” says Dr. Snook. “We used lessons learned in the first study to modify the vaccine to hopefully make it even more effective.”
Since starting the trial, the researchers found that cancers other than colorectal cancer also express GUCY2C, including gastric, esophageal and pancreatic cancer. These are actually among the deadliest cancers. In fact, together with colorectal cancer, these four cancer types account for 20 percent of all cancer-related deaths.
“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” says Dr. Snook.
The Latest on: Colorectal cancer vaccine
via Google News
The Latest on: Colorectal cancer vaccine
- Cancer Immunotherapy Market 2020 Clinical Survey Report – Roche, Bayer, Eli Lilly, Merck, Novartison February 1, 2020 at 12:39 am
The Cancer Immunotherapy Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants ...
- Mass cervical cancer vaccine deployment could save over 60 million lives in next 100 yearson January 31, 2020 at 8:52 am
Two latest studies point at the fact that rapid deployment of cervical cancer vaccines can avoid over 70 million cases ... ranking after breast cancer (2·1 million cases), colorectal cancer (0·8 ...
- Cancer Immunotherapy Market is Expected to Garner Higher Revenues between 2020-2025on January 30, 2020 at 9:55 am
New York, January 30, 2020: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled ...
- Cervical Cancer: Deadly But Avoidableon January 30, 2020 at 8:43 am
PLAINS TOWNSHIP, LUZERNE COUNTY (WBRE/WYOU-TV) — When it comes to women and cancer, the most common types are breast, colon and lung ... He credits that largely in part to the vaccine for Human ...
- Cancer Immunotherapy Market Size to Hit US$ 115.4 Bn by 2026on January 30, 2020 at 6:30 am
Vaccines, Checkpoint Inhibitors, Cell Therapies, Immunomodulators; By Application: Breast Cancer: Lung Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma ...
- New Partnership Could Eventually Lead To ‘One-Size-Fits-All’ Cancer Vaccineson January 30, 2020 at 4:15 am
Kevin Pojasek, Ervaxx CEO, said the collaboration with the Cardiff University research group “shows early but enormous potential for the treatment of cancers.” ...
- New partnership could result in "one-size-fits-all" cancer treatmenton January 29, 2020 at 1:11 am
PanARMENIAN.Net - British scientists who announced last week their discovery of a new type of cancer-killing T-cell have entered a partnership with a biotechnology company pioneering the use of Dark ...
- Editorial: How to wipe out cervical cancer in Chicagoon January 24, 2020 at 3:57 pm
If there were a highly effective vaccine against breast cancer, lung cancer or colon cancer, Americans would throng their doctor’s offices and pharmacy clinics to get it. After heart disease, cancer ...
- The Centers for Disease Control and Prevention says that Cervical Cancer CAN be Preventedon January 22, 2020 at 7:40 am
Cervical cancer is very preventable with the availability of screening tests and the HPV vaccine. When detected early ... screenings for cancers such as breast, cervical, and colorectal cancers.
- Cancer Advances Inc: Cancer Advances, Inc. Announces Poster Presentation at ASCO GIon January 21, 2020 at 6:29 pm
About Polyclonal Antibody Stimulator (PAS) PAS vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, colorectal, and liver. The vaccine is a ...
via Bing News